WO2000021550A3 - Methods and compositions for treating neurodegenerative diseases - Google Patents

Methods and compositions for treating neurodegenerative diseases

Info

Publication number
WO2000021550A3
WO2000021550A3 PCT/US1999/024221 US9924221W WO0021550A3 WO 2000021550 A3 WO2000021550 A3 WO 2000021550A3 US 9924221 W US9924221 W US 9924221W WO 0021550 A3 WO0021550 A3 WO 0021550A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
relates
neurodegenerative diseases
compositions
cdk
Prior art date
Application number
PCT/US1999/024221
Other languages
French (fr)
Other versions
WO2000021550A8 (en
WO2000021550A2 (en
Inventor
Li-Huei Tsai
Gentry N Patrick
Ming Sum Lee
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of WO2000021550A2 publication Critical patent/WO2000021550A2/en
Publication of WO2000021550A3 publication Critical patent/WO2000021550A3/en
Publication of WO2000021550A8 publication Critical patent/WO2000021550A8/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to methods of preventing or treating neurodegenerative diseases by administering an antagonist or inhibitor of p25. In particular, the invention relates to methods of preventing or treating a neurodegenerative disease by administering a calpain antagonist or inhibitor, or a cation antagonist or inhibitor, which reduces the truncation or conversion of p35 to p25. It also relates to p.35 and antibodies directed to p.25 and cdk 5. It relates to methods of inhibiting p25/cdk association, cdk 5 deregulation and phosphorylation of tan. Methods of assessing neurodegeneratives diseases using p 25 are provided.
PCT/US1999/024221 1998-10-13 1999-10-13 Methods and compositions for treating neurodegenerative diseases WO2000021550A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10397598P 1998-10-13 1998-10-13
US60/103,975 1998-10-13
US13663199P 1999-05-27 1999-05-27
US60/136,631 1999-05-27

Publications (3)

Publication Number Publication Date
WO2000021550A2 WO2000021550A2 (en) 2000-04-20
WO2000021550A3 true WO2000021550A3 (en) 2000-07-27
WO2000021550A8 WO2000021550A8 (en) 2000-09-21

Family

ID=26801051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/024221 WO2000021550A2 (en) 1998-10-13 1999-10-13 Methods and compositions for treating neurodegenerative diseases

Country Status (1)

Country Link
WO (1) WO2000021550A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ656500A0 (en) * 2000-03-28 2000-04-20 Autogen Pty Ltd A method of treatment and agents for same
US6756385B2 (en) * 2000-07-31 2004-06-29 Pfizer Inc. Imidazole derivatives
GT200100147A (en) * 2000-07-31 2002-06-25 IMIDAZOL DERIVATIVES
AU2001278084A1 (en) 2000-07-31 2002-02-13 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
DE60140074D1 (en) * 2000-12-14 2009-11-12 Burnham Inst Non-apoptotic forms of cell death and method of modulation
GB0620695D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Composition and methods for the treatment of nurdegenerative disease
GB0620705D0 (en) 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
WO2010141710A2 (en) * 2009-06-03 2010-12-09 The Board Of Regents Of The University Of Texas System Antibodies that bind selectively to p25 and uses therefor
US20120156180A1 (en) * 2009-08-10 2012-06-21 The Board Of Trustees Of The University Of Illinois Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
US8597660B2 (en) 2010-09-29 2013-12-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Therapeutic approach to neurodegenerative disorders using a TFP5-peptide
CN105560285A (en) * 2016-01-11 2016-05-11 东莞松山湖明珠实验动物科技有限公司 Application of neural stem cells in mediator influenced expression of protein P25 and P35

Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
WO1992011850A2 (en) * 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
EP0580161A1 (en) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Prophylactic and therapeutic treatment of Alzheimer's disease
EP0623627A1 (en) * 1993-04-28 1994-11-09 Mitsubishi Chemical Corporation Sulfonamide derivatives
WO1995011240A1 (en) * 1993-10-22 1995-04-27 Smithkline Beecham Plc Amine derivatives as calcium channel antagonists
WO1995033723A1 (en) * 1994-06-02 1995-12-14 Smithkline Beecham Plc Phenoxyalkyl substituted piperidines, pyrrolidines, morpholines and thiomorpholines as calcium channel antagonists
WO1996021655A2 (en) * 1995-01-11 1996-07-18 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin b inhibitors
WO1996021641A1 (en) * 1995-01-13 1996-07-18 Smithkline Beecham Plc Enantiomers of 1-(3,4-dichlorobenzyl)-2-methylaminoindane
US5554767A (en) * 1993-05-21 1996-09-10 Warner-Lambert Company Alpha-mercaptoacrylic acid derivatives having calpain inhibitory activity
WO1997010210A1 (en) * 1995-09-12 1997-03-20 Smithkline Beecham Plc Tricyclic pyrrolidine derivatives as calcium channel antagonists
WO1997020842A1 (en) * 1995-12-01 1997-06-12 Centre National De La Recherche Scientifique (C.N.R.S.) Novel purine derivatives having, in particular, antiproliferative properties, and biological uses thereof
WO1997048394A1 (en) * 1996-06-19 1997-12-24 Smithkline Beecham Plc Combination of ropinirole and l-dopa for use in the treatment of parkinson's disease
WO1998001129A1 (en) * 1996-07-10 1998-01-15 Mitsubishi Chemical Corporation Preventives or remedies for neurodegenerative diseases
WO1998012210A1 (en) * 1996-09-23 1998-03-26 Synphar Laboratories Inc. 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
WO1998020736A1 (en) * 1996-11-12 1998-05-22 University Of South Florida VASOACTIVE EFFECTS AND FREE RADICAL GENERATION BY β-AMYLOID PEPTIDES
WO1998025883A1 (en) * 1996-12-11 1998-06-18 Basf Aktiengesellschaft Ketobenzamides as calpain inhibitors
WO1998041092A1 (en) * 1997-03-14 1998-09-24 Smithkline Beecham Corporation Novel indolecarboxamides, pharmaceutical compositions and methodsof inhibiting calpain

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
WO1992011850A2 (en) * 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
EP0580161A1 (en) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Prophylactic and therapeutic treatment of Alzheimer's disease
EP0623627A1 (en) * 1993-04-28 1994-11-09 Mitsubishi Chemical Corporation Sulfonamide derivatives
US5554767A (en) * 1993-05-21 1996-09-10 Warner-Lambert Company Alpha-mercaptoacrylic acid derivatives having calpain inhibitory activity
WO1995011240A1 (en) * 1993-10-22 1995-04-27 Smithkline Beecham Plc Amine derivatives as calcium channel antagonists
WO1995033723A1 (en) * 1994-06-02 1995-12-14 Smithkline Beecham Plc Phenoxyalkyl substituted piperidines, pyrrolidines, morpholines and thiomorpholines as calcium channel antagonists
WO1996021655A2 (en) * 1995-01-11 1996-07-18 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin b inhibitors
WO1996021641A1 (en) * 1995-01-13 1996-07-18 Smithkline Beecham Plc Enantiomers of 1-(3,4-dichlorobenzyl)-2-methylaminoindane
WO1997010210A1 (en) * 1995-09-12 1997-03-20 Smithkline Beecham Plc Tricyclic pyrrolidine derivatives as calcium channel antagonists
WO1997020842A1 (en) * 1995-12-01 1997-06-12 Centre National De La Recherche Scientifique (C.N.R.S.) Novel purine derivatives having, in particular, antiproliferative properties, and biological uses thereof
WO1997048394A1 (en) * 1996-06-19 1997-12-24 Smithkline Beecham Plc Combination of ropinirole and l-dopa for use in the treatment of parkinson's disease
WO1998001129A1 (en) * 1996-07-10 1998-01-15 Mitsubishi Chemical Corporation Preventives or remedies for neurodegenerative diseases
WO1998012210A1 (en) * 1996-09-23 1998-03-26 Synphar Laboratories Inc. 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
WO1998020736A1 (en) * 1996-11-12 1998-05-22 University Of South Florida VASOACTIVE EFFECTS AND FREE RADICAL GENERATION BY β-AMYLOID PEPTIDES
WO1998025883A1 (en) * 1996-12-11 1998-06-18 Basf Aktiengesellschaft Ketobenzamides as calpain inhibitors
WO1998041092A1 (en) * 1997-03-14 1998-09-24 Smithkline Beecham Corporation Novel indolecarboxamides, pharmaceutical compositions and methodsof inhibiting calpain

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 199809, Derwent World Patents Index; Class B03, AN 1998-100810, XP002136734 *
IMAHORI K ET AL: "Physiology and pathology of tau protein kinases in relation to Alzheimer's disease.", JOURNAL OF BIOCHEMISTRY, vol. 121, no. 2, February 1997 (1997-02-01), pages 179 - 188, XP002136731 *
LEE KI-YOUNG ET AL: "Interaction of cyclin-dependent kinase 5 (Cdk5) and neuronal Cdk5 activator in bovine brain.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 271, no. 3, 19 January 1996 (1996-01-19), pages 1538 - 1543, XP002136729 *
MANDELKOW E: "Alzheimer 's disease. The tangled tale of tau.", NATURE, vol. 402, no. 6762, 9 December 1999 (1999-12-09), pages 588 - 589, XP002136733 *
NAKAMURA S ET AL: "p35-nck5a and cyclin-dependent kinase 5 colocalize in Lewy bodies of brains with Parkinson's disease.", ACTA NEUROPATHOLOGICA, vol. 94, no. 2, August 1997 (1997-08-01), pages 153 - 157, XP000906828 *
PATRICK GENTRY N ET AL: "Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration.", NATURE, vol. 402, no. 6762, 9 December 1999 (1999-12-09), pages 615 - 622, XP002136732 *
UCHIDA T ET AL: "Precursor of cdk5 activator, the 23 kDa subunit of tau protein kinase II: Its sequence and developmental change in brain.", FEBS LETTERS, vol. 355, no. 1, 21 November 1994 (1994-11-21), pages 35 - 40, XP002136730 *
WANG KKW ET AL.: "CALPAIN INHIBITION: AN OVERVIEW OF ITS THERAPEUTIC POTENTIAL", TRENDS IN PHARMACOLOGICAL SCIENCES, vol. 15, no. 11, November 1994 (1994-11-01), pages 412 - 417, XP000568894 *

Also Published As

Publication number Publication date
WO2000021550A8 (en) 2000-09-21
WO2000021550A2 (en) 2000-04-20

Similar Documents

Publication Publication Date Title
WO1998022494A3 (en) METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS
HUP0101627A3 (en) Pharmaceutical compositions for treating neuropsychiatric disorders
GB0129260D0 (en) Pharmaceutical compositions and their uses
WO1998028268A3 (en) CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
MX9606546A (en) INHIBITORS OF INTERLEUKIN-1'beta' CONVERTING ENZYME.
AU3652102A (en) Compounds and their uses
WO2001079459A3 (en) Polypeptides having haloperoxidase activity
PL344861A1 (en) Trazinic angiogenesis inhibitiors
WO2002085285A3 (en) Methods and reagents for regulating bone and cartilage formation
CA2284170A1 (en) Identification of agents for use in the treatment of alzheimer's disease
NZ235155A (en) Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical
WO2000021550A3 (en) Methods and compositions for treating neurodegenerative diseases
NZ506771A (en) Modified factor viii
WO2003057145A3 (en) SUBSTITUTED 4,9-DIHYDROCYCLOPENTA[imn]PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES
MX9804588A (en) Use of halogen bleach-comprising compositions for improved mildness to the skin.
GB9712966D0 (en) Novel chalcones
WO2001004116A3 (en) Neurotrophic pyrrolidines and piperidines, and related compositions containing them
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
HRP980097A2 (en) Combinatory compositions for the treatment of dementia
IL121096A0 (en) Pharmaceutical compositions for the treatment of liver disease
WO2001041709A3 (en) Methods for treating cell death diseases and inflammation
WO2001047505A3 (en) Use of azoles for preventing skin cancer
WO2000033788A3 (en) Substituted nitrogen heterocyclic compounds and therapeutic uses thereof
WO1999056736A3 (en) Apoptosis-inducing compounds
WO2001034639A3 (en) β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: C1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
122 Ep: pct application non-entry in european phase
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)